Page 7 of 29
PACE - manuscript for review
receiving different agents, the cumulative dose of norepinephrine equivalents (NE Eq) was calculated as has been 12, 13 with a conversion factor for angiotensin II of 1 ng per 0.1 mcg of norepinephrine based upon the ATHOS-3 trial (Supplement Table 1).13 All 12 lead electrocardiograms (ECGs) recorded during admission were reviewed by a board certified cardiologist to determine the development of atrial arrhythmias. Participants with ECG documentation of a new-onset atrial fibrillation, atrial flutter, or atrial tachycardia were labeled as having an atrial tachyarrhythmia.
Outcomes
We collected data on in-hospital mortality as well the development of hemodynamic compromise following atrial tachyarrhythmia. To determine hemodynamic compromise in those with new-onset atrial tachyarrhythmia, the maximum NE Eq doses of vasopressor recorded the hour before the onset of atrial tachyarrhythmia were compared with the maximum NE Eq dose of vasopressors during the hour after the onset of these arrhythmias. Participants were classified as having hemodynamic compromise following atrial tachyarrhythmia if their NE Eq vasopressor dose requirement increased or if direct current cardioversion was performed within one hour of acute arrhythmia onset.
Statistical analyses
described
previously